| First Author | Du H | Year | 2021 |
| Journal | iScience | Volume | 24 |
| Issue | 3 | Pages | 102169 |
| PubMed ID | 33665583 | Mgi Jnum | J:306830 |
| Mgi Id | MGI:6717713 | Doi | 10.1016/j.isci.2021.102169 |
| Citation | Du H, et al. (2021) Suppression of ELF4 in ulcerative colitis predisposes host to colorectal cancer. iScience 24(3):102169 |
| abstractText | Ulcerative colitis (UC) is a chronic inflammatory bowel disease, characterized by relapsing and remitting colon mucosal inflammation. For patients suffering from UC, a higher risk of colon cancer has been widely recognized. Here, we found that Elf4 (-/-) mice developed colon tumors with 3 cycles of dextran sulfate sodium salt (DSS) treatment alone. We further showed that ELF4 suppression was prevalent in both patients with UC and DSS-induced mice models, and this suppression was caused by promoter region methylation. ELF4, upon PARylation by PARP1, transcriptionally regulated multiple DNA damage repair machinery components. Consistently, ELF4 deficiency leads to more severe DNA damage both in vitro and in vivo. Oral administration of montmorillonite powder can prevent the reduction of ELF4 in DSS-induced colitis models and lower the risk of colon tumor development during azoxymethane (AOM) and DSS induced colitis-associated cancer (CAC). These data provided additional mechanism of CAC initiation and supported the "epigenetic priming model of tumor initiation". |
